Editas Medicine EDIT reported a loss of 55 cents per share in the fourth quarter of 2024, wider than the Zacks Consensus ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Stifel pointed out that during Vertex’s last major investment cycle from mid-2021 to mid-2023, the stock remained range-bound in the low $20s, with ARR growth steady but not accelerating.

KING OF PRUSSIA, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) today announced that it will host an Investor Day on Wednesday, March 19, in Philadelphia, PA. The event will ...

"If we do our jobs right, and you come back a year from now, this place is going to be a buzzing hive" -- Vertex Executive Director Samantha Miles.

During Florida Institute of Technology President John Nicklow's interview activities leading up to his April 2023 hiring ... and Innovative Design as Vertex, a new "applied innovation hub." ...

With that context in mind, consider that Eli Lilly's revenue growth has not dipped below 20% since mid-2023. LLY Operating ... opportunities Keith Speights (Vertex Pharmaceuticals): Vertex ...

Approximately 125 million opioid prescriptions were dispensed to American patients in 2023 to treat moderate to severe pain, per the CDC. Find out which stock just plummeted to the bottom of the ...

A simple calendar can’t be a security risk, right? Wrong. If you buy something using links in our stories, we may earn a commission. This helps support our journalism. Learn more. Please also ...